SCHEMBL184251

SCHEMBL184251

NS(=O)(=O)c1ccccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.61
CA2 P00918 13/20 0.58
CA1 P00915 10/20 0.58
CA9 Q16790 9/20 0.58
CA12 O43570 6/20 0.58
CA5A P35218 5/20 0.58
CA6 P23280 4/20 0.58
CA4 P22748 4/20 0.58
CA5B Q9Y2D0 4/20 0.58
CA7 P43166 3/20 0.58
CA14 Q9ULX7 3/20 0.58
CYP2C9 P11712 2/20 0.58
LDHA P00338 1/20 0.56
STAT3 P40763 1/20 0.53
PTGES2 Q9H7Z7 1/20 0.46
CA3 P07451 2/20 0.46
PLA2G7 Q13093 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
HSD17B10 Q99714 2/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29965023 1.00 CDK2 (0.61) CDK2CA2CA1CA9CA12
SCHEMBL11168990 0.91 CDK2 (0.53) CDK2CA2CA1CA9CA12
SCHEMBL202947 0.83 CA2 (0.70) CDK2CA2CA1CA9CA12
SCHEMBL28882144 0.81 STAT3 (0.56) CDK2CA2CA1CA9CA12
SCHEMBL29381412 0.81 TDP1 (0.50) CDK2CA2CA1CA9CA12
SCHEMBL190005 0.81 TDP1 (0.50) CDK2CA2CA1CA9CA12
SCHEMBL18837 0.81 TDP1 (0.50) CDK2CA2CA1CA9CA12
SCHEMBL11149914 0.81 CA2 (0.47) CDK2CA2CA1CA9CA12
SCHEMBL10749655 0.80 CA2 (0.67) CDK2CA2CA1CA9CA12
SCHEMBL10750176 0.80 CA2 (0.67) CDK2CA2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 US claimed
WO-2021101927-A1 WDR5-MYC INHIBITORS VANDERBILT UNIVERSITY (US) 2021-05-27 WO claimed
CN-110642791-A Sulfonylurea compound, preparation method thereof and application thereof in preparing herbicide 南开大学 2020-01-03 CN claimed
EP-2504003-A1 NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION Cardioxyl Pharmaceuticals Inc. (US) 2012-10-03 EP claimed
WO-2011063400-A1 NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION CARDIOXYL PHARMACEUTICALS, INC. (US) 2011-05-26 WO claimed
WO-2011063339-A1 NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION CARDIOXYL PHARMACEUTICALS, INC. (US) 2011-05-26 WO claimed
EP-1998761-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS Johns Hopkins University School of Medicine (US) 2008-12-10 EP claimed
CN-100439329-C 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing them and intermediates for their preparation KISSEI PHARMACEUTICAL (JP) 2008-12-03 CN claimed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP claimed
WO-2007109175-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) 2007-09-27 WO claimed
US-20050154231-A1 Tamsulosin derivative RANBAXY LABORATORIES LIMITED (IN) 2005-07-14 US claimed
EP-1501793-A1 TAMSULOSIN DERIVATIVE RANBAXY LABORATORIES, LTD. (IN) 2005-02-02 EP claimed
EP-1436371-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING Call, Krimhild (DE) 2004-07-14 EP claimed
US-6727359-B2 REACTING PHENOXIDE SULFONYLCHLORIDE AND ACETOACETAMIDE-N-SULFONYL PHENOXIDE AND AMMONIA USING CATALYST BDL CORPORATION 2004-04-27 US claimed
CN-1468215-A 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation ����ҩƷ��ҵ��ʽ���� 2004-01-14 CN claimed
WO-2003093227-A1 TAMSULOSIN DERIVATIVE RANBAXY LABORATORIES LIMITED (IN) 2003-11-13 WO claimed
US-20030065172-A1 Composition comprising 6-methyl-3,4dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide, its salts, preparation thereof and uses therefor BDL CORPORATION 2003-04-03 US claimed
WO-2002099023-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING CALL, KRIMHILD (DE) 2002-12-12 WO claimed
EP-0044807-B1 N-PHENYLSULFONYL-N'-PYRIMIDINYL- AND -TRIAZINYL UREAS CIBA-GEIGY AG (CH) 1985-11-21 EP claimed
EP-0044212-A1 Herbicidal o-alkylsulfonyloxy- and o-alkylsulfonylamino-benzenesulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-01-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154231-A1 Tamsulosin derivative ADRB1, ADRA1B, ADRA2B CDK2 3942/4885CA2 3014/4885CA1 4270/4885
US-20030065172-A1 Composition comprising 6-methyl-3,4dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide, its salts, preparation thereof and uses therefor PDXK, ITK, KHK CDK2 198/4885CA2 1215/4885CA1 2380/4885
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS CNR1, CDR2, SMN1; SMN2 CDK2 2161/4885CA2 240/4885CA1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.